New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 8, 2014
17:04 EDTSLXPSalix to combine with Cosmo Technologies
Salix Pharmaceuticals and Cosmo Pharmaceuticals announced a definitive merger agreement under which Salix will combine with Cosmo Technologies, a subsidiary of Cosmo. Under the terms of the agreement, Salix will become a wholly-owned subsidiary of Irish domiciled Cosmo Tech, which will change its name to Salix Pharmaceuticals, plc and is expected to have its ordinary shares listed and traded on the NASDAQ Global Select Market. The transaction is expected to be modestly accretive to Salix’s EPS in FY16 and increasingly accretive thereafter. Salix Pharmaceuticals, plc will own Cosmo’s U.S. patents for rifamycin MMX, methylene blue MMX and Uceris, and have specified rights of negotiation with respect to all products Cosmo or its affiliates seek to develop or commercialize in the U.S. In addition, Salix Pharmaceuticals, plc will acquire Cosmo’s patents for rifamycin MMX in Canada, specified Latin American countries, India, China, Japan and the rest of the Far East, excluding Australia and New Zealand, and Cosmo’s patents for Uceris in Japan. Upon completion of the merger, shareholders of Salix are expected to own slightly less than 80% of the ordinary shares of Salix Pharmaceuticals, plc and Cosmo is expected to own slightly more than 20%. Shareholders of Salix will receive one ordinary share of Salix Pharmaceuticals, plc in exchange for each share of Salix Pharmaceuticals, Ltd common stock they own at closing. In connection with the merger, Cosmo will continue to supply Uceris to Salix and will also supply rifamycin MMX and methylene blue MMX. Additionally, Cosmo will have the right to designate one director to serve on the board of Salix Pharmaceuticals, plc and will be subject to certain standstill provisions for at least 10 years following the completion of the merger. The transaction, which will be taxable to Salix’s shareholders, is expected to close in Q4.
News For SLXP From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent SLXP news | >>
March 16, 2015
12:18 EDTSLXPProgenics Relistor SI royalty loss transient, says Brean Capital
Subscribe for More Information
10:58 EDTSLXPValeant price hike likely ends Salix saga, says UBS
UBS believes the race for Salix (SLXP) is likely over now that Valeant (VRX) has increased its offer price, as expected. The firm said it will still like both Valeant (VRX) and Endo (ENDP) if this is how things end, as it believes the deal is still a very good one for Valeant despite the higher price and it expects Endo to find another deal that should be accretive. UBS has Buy ratings on both Valeant and Endo Health.
10:18 EDTSLXPValeant should win Salix with increased offer, says Cantor
Subscribe for More Information
10:07 EDTSLXPHigh option volume stocks
Subscribe for More Information
09:24 EDTSLXPEndo withdraws proposal for Salix
Subscribe for More Information
09:22 EDTSLXPOn The Fly: Pre-market Movers
Subscribe for More Information
08:17 EDTSLXPValeant rises 1% after sweetening Salix takeover offer
Subscribe for More Information
08:06 EDTSLXPValeant ses Salix deal closing on April 1
08:05 EDTSLXPValeant raises offer price for Salix to $173 per share from $158
Subscribe for More Information
08:04 EDTSLXPValeant, Salix agree on amended terms to merger agreement
Subscribe for More Information
07:50 EDTSLXPSalix trading halted, pending news
Subscribe for More Information
07:50 EDTSLXPValeant to raise offer for Salix to $173 per share, DJ reports
Dow Jones cites sources.
March 13, 2015
15:50 EDTSLXPValeant announces HSR clearance for acquisition of Salix
Valeant Pharmaceuticals (VRX) announced that it has received early termination of the applicable waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 with respect to its proposed acquisition of Salix Pharmaceuticals (SLXP). The expiration of the waiting period satisfies one of the conditions to consummate the tender offer and Valeant expects to be in the position to close the transaction on April 1.
13:46 EDTSLXPValeant to raise Salix bid above $160 per share after Endo entry, NYT says
In response to Endo (ENDP) making a rival bid for Salix (SLXP), Valeant Pharmaceuticals (VRX) now plans to team up with Bill Ackman's Pershing Square and other top shareholders to raises its bid for Salix to above $160 per share, all in cash, according to The New York Times, citing people briefed on the matter. The exact price of Valeant’s raised offer was not yet known, the report stated. Salix shares are down about 1% to $168.88 in afternoon trading. Reference Link
13:43 EDTSLXPValeant seen hiking Salix bid above $160 per share cash, NYT says
Subscribe for More Information
10:51 EDTSLXPOptions with increasing implied volatility
Options with increasing implied volatility: PVA BBEP SLXP ENDP MYL BBBY TEVA ZTS
08:14 EDTSLXPAckman says does not view Endo bid for Salix as credible
Subscribe for More Information
08:13 EDTSLXPAckman says Endo would be very highly levered with Salix deal
Bill Ackman of Pershing Square is speaking on CNBC.
08:11 EDTSLXPAckman says Valeant CEO will not overpay for Salix
Bill Ackman of Pershing Square is speaking on CNBC.
05:47 EDTSLXPStocks with implied volatility movement; SLXP MNKD
Stocks with implied volatility movement; Salix (SLXP) 20, Teva (TEVA) 27 according to iVolatility.
1 | 2 | all recent SLXP news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use